Regulatory Agency's Fiscal Transparency and Refined User Fee Structure

The U.S. Food and Drug Administration (FDA) will hold its annual public meeting on June 23, 2026, to discuss the fiscal transparency of the Prescription Drug User Fee Act (PDUFA VII), the Biosimilar User Fee Act (BsUFA III), and the Generic Drug User Fee Act (GDUFA III). This meeting will disclose the Resource Capacity Planning (RCP) and the performance of the modernized time reporting system to enhance regulatory credibility. In fiscal year 2026, the base revenue for PDUFA is approximately $1.43 billion, serving as a crucial resource to support the FDA's independent new drug approval infrastructure.

Pfizer's New Drug Elrexfio and the Economics of Rising Regulatory Costs

For large pharmaceutical companies such as Pfizer (PFE) and Johnson & Johnson (JNJ), the FY 2026 NDA/BLA application fee is $4.68 million per application, an 8.6% increase from the previous year, increasing the financial burden. For example, for new drugs like Pfizer's Elrexfio (elranatamab-bcmm, a BCMA-targeting bispecific antibody) for multiple myeloma, which competes with drugs like Tecvayli (teclistamab-cqyv), delays in approval result in significant opportunity costs. With the increase in fees, the FDA must strictly adhere to the review timeline to effectively manage the return on R&D investment in the approximately $22 billion multiple myeloma market.

Amgen and Viatris Leading the Way in Promoting Biosimilar Price Competition

In the biosimilar sector, the FY 2026 BsUFA clinical data inclusion application fee is reduced by 18.4% to $1.20 million, lowering regulatory barriers. This helps companies like Amgen (AMGN) and Viatris (VTRS), which develop generic drugs, to quickly enter the market for off-patent drugs. For example, the fee reduction in the process of approving Amgen's Wezlana (ustekinumab-auub), a biosimilar to Johnson & Johnson's Stelara (ustekinumab) with annual sales of $10.8 billion, as an interchangeable product, leads to improved development margins. The rapid availability of affordable alternative drugs breaks the monopoly structure and contributes to increasing the efficiency of healthcare spending.

Maximizing Capital Efficiency and Changes in Biotech Technology Transfer Deal Terms

The structural increase in regulatory fees also affects the exit strategies and technology transfer (licensing out) deal terms of early-stage biotechs. Due to cost pressures, smaller biotechs are increasingly inclined to license their assets to large pharmaceutical companies in exchange for upfront payments, milestone payments, and royalties at Phase 2 or Phase 3, rather than pursuing independent approvals. This trend of capital efficiency serves as a catalyst for activating capital circulation within the ecosystem by reducing venture capital (VC) investment risk. Improved financing conditions lead to increased employment of R&D personnel, expanding career growth opportunities for new job seekers.

Investment Guidelines in Preparation for the 2027 Fee Program Reauthorization

This public meeting is also an important preliminary negotiation table for amending the next act (FY 2028-2032) after the expiration of the current acts on September 30, 2027. Future diversification of fee pricing criteria and refinement of review performance indicators (KPIs) are expected to have a significant impact on the pipeline competition of individual pharmaceutical companies. Investors should closely monitor how individual companies mitigate the impact of changes in regulatory costs and defend their capital recovery timelines. The increasing financial independence of regulatory agencies also ensures that they remain independent and objective in their scientific reviews, which is a key factor in building long-term market confidence.